NS5A inhibitor
Hepatitis C NS5A inhibitor
- Disrupts viral RNA replication and virion assembly
- Low resistance barrier → always combined with a second class for a durable cure
- Cure rates above 95% in combination regimens
Drugs with this mechanism (6)
- Daclatasvir — Hepatitis C NS5A inhibitor used with sofosbuvir; strong enzyme inducers can undermine antiviral efficacy.
- Elbasvir — Hepatitis C NS5A inhibitor coformulated with grazoprevir; baseline resistance can affect regimen selection.
- Ledipasvir — Hepatitis C NS5A inhibitor (in Harvoni).
- Ombitasvir — Hepatitis C NS5A inhibitor.
- Pibrentasvir — Hepatitis C NS5A inhibitor.
- Velpatasvir — Pan-genotypic hepatitis C NS5A inhibitor (in Epclusa).
Self-check
- Which two viral processes does HCV NS5A inhibition disrupt?
RNA replication and virion assembly. - Why always combine an NS5A inhibitor with a second class?
Its low resistance barrier.
All mechanisms · Open NS5A inhibitor in the interactive console ↗